Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

NCT05607498 is registered in ClinicalTrials.gov with EpimAb Biotherapeutics (Suzhou)Co., Ltd. as lead sponsor.

NCT NCT05607498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Lead sponsor
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 1, 2023
Completion date
March 31, 2026
Enrollment
150 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumors, relapse/refractory lymphoma